Economic burden of COPD: The SCOPE study;Impact économique de la BPCO en France: Étude SCOPE

Revue des Maladies Respiratoires

Volumn 22, Issue 2 C1, 2005, Pages 247-255

  Fournier, M ^a   Tonnel, A B ^b   Housset, B ^c   Huchon, G ^d   Godard, P ^e   Vervloet, D ^f   Huas, D ^g   Durand Zaleski, I ^h   Chanal, I ⁱ   Pribil, C ⁱ   Neukirch, F ^j   Aubier, M ^j   Brambilla, C ^j   Soussan, R ^j   Druais, P L ^j  

^a BEAUJON HOSPITAL   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

^d HÔTEL DIEU   (France)

^e HÔPITAL ARNAUD DE VILLENEUVE   (France)

^f HÔPITAL SAINTE MARGUERITE   (France)

^g UNIVERSITÉ PARIS DESCARTES   (France)

^h Service d'Évaluation des Pratiques   (France)

ⁱ GLAXOSMITHKLINE   (France)

^j NONE

more..

Author keywords

COPD; Economical analysis; France; Health care consumption; Severity staging

Indexed keywords

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COST OF ILLNESS; DISEASE EXACERBATION; DISEASE SEVERITY; ECONOMIC ASPECT; FEMALE; FRANCE; GENERAL PRACTITIONER; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITAL CARE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; PATIENT CARE; PRESCRIPTION; PROSPECTIVE STUDY; QUESTIONNAIRE; RETROSPECTIVE STUDY; ECONOMICS; HOSPITALIZATION;

AGED; FEMALE; FRANCE; HEALTH CARE COSTS; HUMANS; MALE; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 21044445594     PISSN: 07618425     EISSN: None     Source Type: Journal    
DOI: 10.1019/200539984     Document Type: Article

References (24)

1. Vermeire P: The burden of chronic obstructive pulmonary disease. Respir Med 2002; 96: S3-S10.
2. Muir JF: Bronchopneumopathies chroniques obstructives et leurs complications. La revue du Praticien 1995; 45: 2085-97.
3. SPLF (Société de Pneumologie de Langue Française): Actualisation 2003 des recommandations de la SPLF sur la prise en charge de la BPCO: organisation et argumentaire. Rev Mal Respir 2003; 20: 4S7-9.
4. Favre F: Enquête sur l'initialisation des traitements et le suivi des comportements thérapeutiques dans la BPCO, Laboratoire Glaxo-Wellcome, 1999.
5. Pelletier-Fleury N, Lancoe JL, Fleury B, Fardeau M: The cost of treating COPD patients with long term oxygen therapy in a french population. Chest 1996; 110: 411-6.
6. Pechevis M, Fagnani F, Brin S, de Zelicourt M, Moralis M: Infections respiratoires récidivantes du sujet atteint de bronchite chronique obstructive: prise en charge médicale et coûts. Rev Mal Respir 1996; 13: 507-12.
7. Sullivan S, Ramsey SD, Lee TA: The economic burden of COPD. Chest 2000; 117: 5S-9S.
8. Price MJ, Hurell C, Efthimiou J, Medley HV: Healthcare costs of treating exacerbations of chronic obstructive pulmonary disease (COPD). European Respiratory Society 1999.
9. Miravittles M, Murio C, Guerrero T, Gisbert R: Costs of chronic bronchitis and COPD: a 1-year flow-up study. Chest 2003; 123: 784-91.
10. Jansson SA, Andersson F, Borg S, Ericsson A, Jonsson E, Lundback B: Costs of COPD in Sweden according to disease severity. Chest 2002; 122: 1994-2002.
11. Andersson F, Borg S, Jansson AC, Ericsson A, Prutz C, Ronmark E, Lundback: The costs of exacerbations in chronic obstructive pulmonary disease (COPD). Respir Med 2002; 96: 700-8.
12. Wouters EF: The burden of COPD in the Netherlands: results from rhe Confronting COPD survey. Respir Med 2003; 97: S51-9.
13. Halpern MT, Stanford RH, Borker R: The burden of COPD in the U.S.A.: results form the Confronting COPD survey. Respir Med 2003; 97: S81-9.
14. Britton M: The burden of CPD in U.K.: results form the Confronting COPD survey. Respir Med 2003; 97: S71-9.
15. Izquierdo JL: The burden of COPD in Spain: results from the Confronting COPD survey. Respir Med 2003; 97: S61-9.
16. Dal Negro R, Rossi A, Cerveri I: The burden of COPD in Italy: results from the Confronting COPD survey. Respir Med 2003; 97: S43-50.
17. Chapman KR, Bourbeau J, Rance L: The burden of COPD in Canada: results from the COPD Confronting survey. Respir Med 2003; 97: S23-31.
18. Piperno D, Huchon G, Pribil C, Boucot I, Similowski T: The burden of COPD in France: results from the Confronring COPD survey. Respir Med 2003; 97: S33-42.
19. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA: Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 196-204.
20. Société de Pneumologie de Langue Française (SPLF): Recommandations pour la prise en charge des broncho-pneumopathies chroniques obstructives. Rev Mal Respir 1997; 14: 2S7-91.
21. Thiadens HA, De Bock GH, Van Houwelingen JC, Dekker FW, De Waal MW, Springer MP, Postma DS: Can peak expiratory flow measurements reliably identify the presence of airway obstruction and bronchodilatator response as assessed by FEV (1) in primary care patients presenting with a persistant cough? Thorax 1999; 54: 1051-2.
22. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS: Global straregy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global initiative for chronic obstructive lung disease (GOLD). Workshop summary. Am J Respir Crit Care Med 2001; 163: 1256-76.
23. Hilleman DE, Dewan N, Malesker M, Friedman M: Pharmacoeconomic evaluation of COPD. Chest 2000; 118: 1278-85.
24. Huchon G: Données épidémiologiques sur la bronchite chronique en France. Presse Médicale 2001; 30: 7-10.